Compare Orchid Pharma with WYETH - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ORCHID PHARMA vs WYETH - Comparison Results

ORCHID PHARMA     Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

WYETH 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ORCHID PHARMA WYETH ORCHID PHARMA/
WYETH
 
P/E (TTM) x -163.5 27.7 - View Chart
P/BV x 46.9 5.3 876.5% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ORCHID PHARMA   WYETH
EQUITY SHARE DATA
    ORCHID PHARMA
Sep-13
WYETH
Mar-13
ORCHID PHARMA/
WYETH
5-Yr Chart
Click to enlarge
High Rs1941,044 18.6%   
Low Rs35818 4.3%   
Sales per share (Unadj.) Rs276.5298.6 92.6%  
Earnings per share (Unadj.) Rs-79.257.2 -138.4%  
Cash flow per share (Unadj.) Rs-43.558.4 -74.4%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs53.9249.5 21.6%  
Shares outstanding (eoy) m70.4522.72 310.1%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x0.43.1 13.3%   
Avg P/E ratio x-1.416.3 -8.9%  
P/CF ratio (eoy) x-2.615.9 -16.5%  
Price / Book Value ratio x2.13.7 56.9%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m8,06721,157 38.1%   
No. of employees `0002.80.5 569.1%   
Total wages/salary Rs m2,527400 631.8%   
Avg. sales/employee Rs Th6,956.113,787.4 50.5%   
Avg. wages/employee Rs Th902.5813.0 111.0%   
Avg. net profit/employee Rs Th-1,993.02,643.3 -75.4%   
INCOME DATA
Net Sales Rs m19,4776,783 287.1%  
Other income Rs m407353 115.5%   
Total revenues Rs m19,8847,136 278.6%   
Gross profit Rs m1,1031,617 68.2%  
Depreciation Rs m2,51927 9,470.7%   
Interest Rs m5,2276 95,032.7%   
Profit before tax Rs m-6,2361,938 -321.8%   
Minority Interest Rs m200-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m511-5 -10,019.6%   
Tax Rs m-125632 -19.8%   
Profit after tax Rs m-5,5801,301 -429.1%  
Gross profit margin %5.723.8 23.7%  
Effective tax rate %2.032.6 6.2%   
Net profit margin %-28.719.2 -149.4%  
BALANCE SHEET DATA
Current assets Rs m11,0146,984 157.7%   
Current liabilities Rs m32,0602,056 1,559.4%   
Net working cap to sales %-108.172.6 -148.7%  
Current ratio x0.33.4 10.1%  
Inventory Days Days9599 95.6%  
Debtors Days Days3424 140.2%  
Net fixed assets Rs m29,440244 12,050.7%   
Share capital Rs m705227 310.1%   
"Free" reserves Rs m2,0435,441 37.5%   
Net worth Rs m3,8005,668 67.0%   
Long term debt Rs m9,01825 36,071.6%   
Total assets Rs m46,5107,901 588.7%  
Interest coverage x-0.2353.3 -0.1%   
Debt to equity ratio x2.40 53,805.1%  
Sales to assets ratio x0.40.9 48.8%   
Return on assets %-0.816.5 -4.6%  
Return on equity %-146.922.9 -640.0%  
Return on capital %-3.734.0 -11.0%  
Exports to sales %37.90.2 17,361.2%   
Imports to sales %22.636.3 62.2%   
Exports (fob) Rs m7,37815 49,848.6%   
Imports (cif) Rs m4,4062,465 178.7%   
Fx inflow Rs m7,51315 49,429.6%   
Fx outflow Rs m5,6492,677 211.0%   
Net fx Rs m1,865-2,662 -70.0%   
CASH FLOW
From Operations Rs m1,682923 182.2%  
From Investments Rs m-9,860317 -3,111.5%  
From Financial Activity Rs m6,644-481 -1,381.2%  
Net Cashflow Rs m-1,535759 -202.2%  

Share Holding

Indian Promoters % 32.3 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 4.6 11.3 40.7%  
FIIs % 3.3 7.2 45.8%  
ADR/GDR % 4.6 0.0 -  
Free float % 55.3 30.4 181.9%  
Shareholders   84,811 21,978 385.9%  
Pledged promoter(s) holding % 54.9 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ORCHID PHARMA With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  CADILA HEALTHCARE  NOVARTIS  DR. DATSONS LABS  

Compare ORCHID PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ORCHID PHARMA SHARE PRICE


Apr 9, 2021 (Close)

TRACK ORCHID PHARMA

  • Track your investment in ORCHID PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ORCHID PHARMA 8-QTR ANALYSIS

COMPARE ORCHID PHARMA WITH

MARKET STATS